PHI-101 administration
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Ovarian Cancer
Conditions
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma
Trial Timeline
Dec 17, 2020 → Dec 31, 2023
NCT ID
NCT04678102About PHI-101 administration
PHI-101 administration is a phase 1 stage product being developed by iBio for Platinum-resistant Ovarian Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04678102. Target conditions include Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04678102 | Phase 1 | UNKNOWN |
Competing Products
16 competing products in Platinum-resistant Ovarian Cancer